They note that this is not a notice of solicitation; rather, it is intended to gauge small businesses’ ability to develop and employ animal models and replacement models for clinical screening purposes.
Animal models are categorized into four groups that include small animals, non-human primates and non-traditional models for infectious diseases and small animal models that are able to be compliant with good laboratory practice requirements. The use of these subjects has allowed continued development and approval of treatments, vaccines, countermeasures against emerging diseases, pathogens that pose a threat to public health and the national biological security.
The notice states that a future indefinite delivery and indefinite quantity solicitation related in this area is expected to be announced in an undetermined timeframe.
Respondents should include their experience in this area, formal training amongst staff, current in-house capabilities and management capability. Companies will need to include information and qualifications of their key personnel, documentation of adequacy and listings of similar work that has been performed at their respective facilities.
Issuers of this notice state that there is no obligation on their part to offer any contract or other form of payment in response to any submission.